Experienced in Neurofibromatosis Type 1 (NF1)

Dr. Prakash Ambady

Neurology
9135 Southwest Barnes Road, Suite 461, 
Portland, OR 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Neurofibromatosis Type 1 (NF1)
9135 Southwest Barnes Road, Suite 461, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Prakash Ambady is a Neurologist in Portland, Oregon. Dr. Ambady is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor. Dr. Ambady is currently accepting new patients.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Neurofibromatosis Type 1 (NF1).

Specialties
Neurology
Licenses
Psychiatry & Neurology in OR
Hospital Affiliations
Providence Portland Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
ATRIO Health
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

9135 Southwest Barnes Road, Suite 461, Portland, OR 97225

Additional Areas of Focus

Dr. Ambady has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS
The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS
Enrollment Status: Recruiting
Publish Date: February 28, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Response Assessment to Pembrolizumab With Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging- A Pilot Study
Response Assessment to Pembrolizumab With Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging- A Pilot Study
Enrollment Status: Terminated
Publish Date: September 09, 2025
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Ferumoxytol, Pembrolizumab
Study Phase: Phase 2
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Biological
Study Drugs: PVSRIPO, Pembrolizumab
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-Check Pilot)
The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-Check Pilot)
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Procedure, Drug, Other, Biological
Study Drug: Ferumoxytol
Study Phase: Phase 2
View 5 Less Clinical Trials

41 Total Publications

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 08, 2024
Similar Doctors
Experienced in Neurofibromatosis Type 1 (NF1)
Dr. John M. Dempster
Neurology | Psychiatry
Experienced in Neurofibromatosis Type 1 (NF1)
Dr. John M. Dempster
Neurology | Psychiatry

Legacy Good Samaritan Hospital And Medical Center

1130 Nw 22nd Ave, Suite 400, 
Portland, OR 
 (4.1 miles away)
503-413-6722
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Dempster is a Neurologist and a Psychiatrist in Portland, Oregon. Dr. Dempster is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Partial Familial Epilepsy, Partial Seizure, Memory Loss, and Seizures. Dr. Dempster is currently accepting new patients.

Experienced in Neurofibromatosis Type 1 (NF1)
Dr. Sarah A. Copeland
Pediatric Neurology | Pediatrics | Neurology
Experienced in Neurofibromatosis Type 1 (NF1)
Dr. Sarah A. Copeland
Pediatric Neurology | Pediatrics | Neurology
500 Ne Multnomah St, Fl 11, 
Portland, OR 
 (5.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sarah Copeland is a Pediatric Neurologist and a Pediatrics provider in Portland, Oregon. Dr. Copeland is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Epilepsy, Sandhoff Disease, Seizures, and Memory Loss. Dr. Copeland is currently accepting new patients.

Dr. David H. Delman
Neurology
Dr. David H. Delman
Neurology

Kaiser Permanente Sunnyside Medical Center

10180 SE Sunnyside Rd, 
Clackamas, OR 
 (11.3 miles away)
503-813-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Delman is a Neurologist in Clackamas, Oregon. Dr. Delman is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Memory Loss, Seizures, Progressive Myoclonic Epilepsy, and Unverricht-Lundborg Syndrome. Dr. Delman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ambady's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 7 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile